The Smartest Dividend Stocks to Buy With $1,000 Right Now

Chevron is an integrated energy company with an impressive yield and an impressive dividend history. Bristol Myers has a high yield, but the drugmaker is out of favor.

The Motley Fool • 19 hours ago

Buy And Hold Portfolio For Next 10 Years: Potential $5,500 Monthly Income

This article presents a diversified, fund-based portfolio targeting market-matching growth and a 6%+ income yield, with lower tech exposure than the S&P 500. The model portfolio, comprising 5 ETFs and 6 CEFs, emphasizes asset class diversification—spanning blue-chip dividends, tech, real estate, gold, materials, energy, and utilities. The portfolio presented uses ahands-off approach, and it is diversified among many asset classes to be able to withstand different economiccycles in the next 10 years.

Seeking Alpha • Dec 13, 2025

Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?

BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.

Zacks Investment Research • Dec 12, 2025

Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors

Bristol Myers Squibb (BMY) closed the most recent trading day at $52.41, moving +2.36% from the previous trading session.

Zacks Investment Research • Dec 12, 2025

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma.

Business Wire • Dec 11, 2025

Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript

Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript

Seeking Alpha • Dec 11, 2025

Bristol Myers Squibb Announces Dividend Increase

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase.

Business Wire • Dec 10, 2025

5 Blue Chip Stocks to Buy Now That Pay Reliable 4%+ Dividends

Investors love high-yield dividend stocks, especially the blue chip variety, because they offer a significant income stream and have massive total return potential.

24/7 Wall Street • Dec 10, 2025

2 Pharmaceutical Stocks to Buy at a Discount

Weight loss drugs are the big story in the pharmaceutical industry today, but other opportunities exist, too. Bristol Myers Squibb isn't focused on weight loss, has an attractive yield, and continues to cover its dividend.

The Motley Fool • Dec 10, 2025

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patients Pumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespective of PD-L1 expression levels Data highlight the potential of pumitamig for patients with TNBC, including PD-L1 low or negative (CPS

GlobeNewsWire • Dec 9, 2025